Details for New Drug Application (NDA): 021518
✉ Email this page to a colleague
NDA 021518 describes VESICARE, which is a drug marketed by Astellas and is included in two NDAs. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the VESICARE profile page.
The generic ingredient in VESICARE is solifenacin succinate. There is one drug master file entry for this compound. Twenty suppliers are listed for this compound. Additional details are available on the solifenacin succinate profile page.
The generic ingredient in VESICARE is solifenacin succinate. There is one drug master file entry for this compound. Twenty suppliers are listed for this compound. Additional details are available on the solifenacin succinate profile page.
Summary for 021518
| Tradename: | VESICARE |
| Applicant: | Astellas |
| Ingredient: | solifenacin succinate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 021518
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 5MG | ||||
| Approval Date: | Nov 19, 2004 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 10MG | ||||
| Approval Date: | Nov 19, 2004 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
